126 related articles for article (PubMed ID: 36401358)
1. Bortezomib induces cellular senescence in A549 lung cancer cells by stimulating telomere shortening.
Wang L; Yin H; Huang S; Huang S; Huang C; Zhang Z; Liu H
Hum Exp Toxicol; 2022; 41():9603271221124094. PubMed ID: 36401358
[TBL] [Abstract][Full Text] [Related]
2. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Li C; Hu J; Li W; Song G; Shen J
Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
[TBL] [Abstract][Full Text] [Related]
3. miR-466 Contributes to the Enhanced Antitumor Effect of Bortezomib on Non-Small-Cell Lung Cancer by Inhibiting CCND1.
Wang WH; Zhan JM; Tang YL; Zhou N; Liu WY; Jiang DW
Chemotherapy; 2022; 67(2):110-122. PubMed ID: 35042223
[TBL] [Abstract][Full Text] [Related]
4. Particulate matter causes telomere shortening and increase in cellular senescence markers in human lung epithelial cells.
Chang-Chien J; Huang JL; Tsai HJ; Wang SL; Kuo ML; Yao TC
Ecotoxicol Environ Saf; 2021 Oct; 222():112484. PubMed ID: 34237641
[TBL] [Abstract][Full Text] [Related]
5. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L; Kraus M; Besse A; Driessen C; Tarantino I
Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
[TBL] [Abstract][Full Text] [Related]
6. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
Shen J; Song G; An M; Li X; Wu N; Ruan K; Hu J; Hu R
Biomaterials; 2014 Jan; 35(1):316-26. PubMed ID: 24125776
[TBL] [Abstract][Full Text] [Related]
7. Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.
Gu JJ; Kaufman GP; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Oncotarget; 2017 Feb; 8(8):12741-12753. PubMed ID: 28055975
[TBL] [Abstract][Full Text] [Related]
8. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
Wu YF; Ou CC; Chien PJ; Chang HY; Ko JL; Wang BY
Phytomedicine; 2019 Mar; 56():94-102. PubMed ID: 30668358
[TBL] [Abstract][Full Text] [Related]
9. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.
Jin S; Li B; Zhang B; Gao X; Jia X; Xu L; Chang S; Hu K; Wang G; Xu Z; Zhang T; Song D; Yang G; Wu X; Zhu H; Huang C; Lu Y; Shi J; Zhu W; Chen G
Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1884-1891. PubMed ID: 38009004
[TBL] [Abstract][Full Text] [Related]
10. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
[TBL] [Abstract][Full Text] [Related]
12. Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: an in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal epithelial cells.
Coelho SC; Almeida GM; Santos-Silva F; Pereira MC; Coelho MA
Expert Opin Drug Deliv; 2016 Aug; 13(8):1075-81. PubMed ID: 27087021
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
14. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
16. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
Liu J; Zhao R; Jiang X; Li Z; Zhang B
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
[TBL] [Abstract][Full Text] [Related]
17. Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells.
Li Y; Dong S; Tamaskar A; Wang H; Zhao J; Ma H; Zhao Y
Oncol Res; 2020 Dec; 28(5):497-507. PubMed ID: 32580819
[TBL] [Abstract][Full Text] [Related]
18. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
Dutta D; Liu J; Wen K; Kurata K; Fulciniti M; Gulla A; Hideshima T; Anderson KC
Blood Cancer J; 2023 Dec; 13(1):184. PubMed ID: 38072962
[TBL] [Abstract][Full Text] [Related]
19. The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
Shen J; Wang R; Wang Q; Zhang M; Liu C; Tao Z; Su G
Aging (Albany NY); 2020 Dec; 13(1):411-423. PubMed ID: 33290262
[TBL] [Abstract][Full Text] [Related]
20. Platinum(II) phenanthroimidazole G-quadruplex ligand induces selective telomere shortening in A549 cancer cells.
Mancini J; Rousseau P; Castor KJ; Sleiman HF; Autexier C
Biochimie; 2016 Feb; 121():287-97. PubMed ID: 26724375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]